# Inotropes, Heart Failure, and Anti-Angina
<!-- toc -->
# Inotropes Big Picture
* Inotropy vs. Chronotropy
  * Inotropy: **Increased Contractility**
  * Chronotropy: **Increased HR**
* How to increase Inotropy?
  * Increase intracellular Ca: **Digoxin, Milrinone**
  * Stimulate B1 receptor on ventricular muscle: **Dopamine, Dobutamine**

## Digoxin/Digitoxin
*MOA (2 Effects):*
* Inhibits Na/K ATPase pump thus inhibiting Na/Ca exchange pump thus indirectly increasing intracellular Ca
  * High Intracellular Ca leads to increased contractility
* Stimulates Vagus nerve- Decreases HR

*Use:*
* CHF (Increases Contractility)
* A. Fib (Depresses SA node and decreases AV node conduction)

*Digitoxin*
* Longer half life
* Liver elimination
* Block Exam: Use in patients with renal failure

### Digoxin Toxicity
* Cholinergic SE
  * Nausea, vomiting, diarrhea, **blurry vision, AV block**
  * **AV block**
* Factors leading to toxicity
  * Renal failure (decreased excretion)
  * Hypokalemia
    * Digoxin binds to K binding site leading to enhanced effect
  * Drug interactions (displaces digoxin from tissue binding)
    * **Amiodarone**, Verapamil
* Treatment of Digoxin Toxicity
  * Normalize K
  * Digibind
  * Atropine/Cardiac pacing

## Dopamine
*MOA:* Stimulates B1 and D1
* B1: Inotropic Effect and BP effect
* D1: Renal vasodilation

*Use:*
* Cardiogenic shock
* Bradycardia
* Acute decompensated CHF

*SE:*
* Tachycardia
* Arrhythmias

## Dobutamine
*MOA:* Stimulates B1 and B2 receptors
* B1: Inotropic effect
* B2: Vasculature vasodilation

*Use:*
* Acute decompensated CHF

*SE:*
* Tachycardia
* Arrhythmias

## Milironone
*MOA:* PDE inhibitor, increases cAMP, leading to increases intracellular Ca, leading to
increased Inotropy in myocytes and vasodilation in vasculature

*Use:* Acute decompensated CHF

*SE:* Arrhythmia, Vasodilation


## Sacubitril/Vaslartan
**Valsartan- ARB**
**Sacubitril**

*MOA:*
* Neprilysin is an endopeptidase that breaks down ANP which is a diuretic and vasodilator
* Sacubitril inhibits Neprilysin leading to decreased ECF volume and BP

## Ivabradine
*MOA:*
* Funny channel blocker
* Funny channel allows Na to slowly enter SA pacemaker cells to depolarize it
* Ivabradine prolongs depolarization slowing heart rate
* Negative chronotropy without negative inotropy
* Reduces cardiac O2 requirement

*Use:*
* Chronic stable angina in patients who can't tolerate BB
* CHF with reduced EF

*SE:* Increased visual brightness

# Congestive Heart Failure
*Classification:*
* Heart Failure with reduced EF (<45%): **Systolic HF**
* Heart Failure with preserved EF: **Diastolic HF**

*Treatment* of Acute Decompensated HF
* Reduce fluid overload: **IV Loop diuretics**
* Increase contractility: **Dobutamine, Milrinone**
* Increase BP and contractility if in cardiogenic shock: **Dopamine**


## Systolic vs. Diastolic HF Treatment
### Systolic CHF Treatment
* **ACE Inhibitors, Beta Blockers, Spironolactone, and potentially Neprilysin Inhibitor**
  * Prevent left ventricular hypertrophy mediated by Angiotensin Il and catecholamines
  * ***All 3 have proven reduced mortality benefit in Systolic CHF***
* **Hydralazine/lsosorbide**
  * Proven mortality benefit for African Americans
* **Digoxin**
  * Improve contractility and reduces hospitalization but no effect on mortality
* **Loop Diuretics**
  * Improve fluid overload but no effect on mortality or hospitalization
### Diastolic CHF Treatment
*  Diuretics and BP Control

**Avoid in Both**
* Non-DHB CCB: **Depresses contractility**
* DHB CCB: **Causes peripheral edema**


# Angina Big Picture
Chest pain due to ischemic myocardium due to coronary artery narrowing or spasm

Mismatch between supply and demand

**Spectrum of Angina**
* Stable: >70% Narrowing of coronary artery, reversible
* Unstable: Incomplete occlusion of coronary artery, reversible
* Prinzmetal (Variant): Coronary artery vasospasm, reversible
* NSTEMI: Subendocardial necrosis, irreversible
* STEMI: Transmural necrosis, irreversible

# Angina Treatment Big Picture
**Goal: Restore balance between supply and demand**
**How?**
* Increase supply
  * Coronary revascularization using balloon angiography and stenting
  * Coronary Artery Bypass Grafting
* Decrease demand- Reduce myocardial O2 consumption (MVO2)
  * Determinants of MVO2= Contractility, Heart rate, Preload (EDV), Afterload (BP)
  * **Reduce contractility & HR**= Beta blockers
  * **Reduce Preload (EDV)**= Nitrates
  * **Reduce Afterload**= DHB CCB

## Antianginals Agents
### Nitrates
**(Nitroglycerin SL, Isosorbide PO)**
**Angina MOA**: Venodilation thus decreasing preload and decreases
End-Diastolic Volume (EDV) thus decreasing myocardial stretch and demand

**Anginal Specific SE:**

* Contraindicated in right ventricular infarct
  * RV becomes preload dependent and nitrates decrease preload
* Reflex Tachycardia increases demand
  * Combined with Beta blockers to blunt reflex tachycardia

### Beta Blockers
* Angina MOA: Decrease HR and contractility thus decreasing myocardial demand
* Negative Chronotropes

### Calcium Channel Blockers
**DHB CCB (Amlodipine, Nifedipine)**

**Antianginal MOA:**
* Arteriolar vasodilators thus decreasing afterload and BP
* Some Coronary arteries vasodilation

*Use:* Stable & ** Prinzmetal Angina***

*A word on Non-DHB CCB (Verapamil and Diltiazem)*
* Same antianginal MOA as DHB CCB
* Clinical practice: Not used for angina due to negative inotropic effect


### Ranolazine
*MOA:* **Inhibits late sodium current**- Phase 2 thus decreasing influx of Ca into
the cell decreasing contractility and wall tension

*Use:* Refractory Angina

*SE:* **QT prolongation**
* Inhibition of Ik channels in phase 3

## Anti-Anginals Physiologic Effects
![Antianginals Pharmacological Treatment](https://d3i71xaburhd42.cloudfront.net/00b6e631506f9eb5048cb71d00783b52adec9ce4/500px/2-Table1-1.png)

## Stable Angina Treatment Algorithm
**Control Atherosclerosis risk factors**
* Smoking cessation
* BP Control
* Decrease atherosclertotic plaque burden: Statins

**Pharmacological**
* Acute attack: sublingual nitrate
* Chronic
  * 1st line: Oral nitrates, beta blockers
  * 2nd line: DHB CCB
  * 3rd line: Ranolazine
  * 4th line: lvabradine
* Refractory
  * Coronary Balloon Angiography and Stenting
  * CABG
